Main Content start here
Main Layout
Report Description

Report Description

Global hormone replacement therapy (HRT) market is expected to rise at a high CAGR during the forecast period, 2024-2028. Growing prevalence of other hormonal imbalance disorders which are common among people of various developing countries in the world are expected to register a lucrative growth to global hormone replacement therapy market in the forecast period. Growth in global geriatric population and certain hormonal disorders such as andropause, hyperthyroidism, hypothyroidism, and others which are associated with people during their elder age are expected to propel the growth of hormone replacement therapy market across the world in the forecast period. Furthermore, improvement in worldwide healthcare infrastructure which are leading to innovations in hormone replacement therapy are further expected to register an impressive growth to global hormone replacement therapy market in the forecast period.

Hormone Replacement Therapy (HRT) is a medical treatment that involves replacing the hormones that are produced in lower quantities in the body especially after treatment of certain types of cancer and menopause in women. Various types of hormone replacement therapy that are commonly performed across the world includes estrogen-only therapy, combination therapy, transdermal therapy, and bioidentical hormone therapy.

The United States of America, Canada, Australia, and several European countries such as France, Italy, and Sweden account for highest number of hormone replacement therapies performed among their population in the forecast period. Several health conditions that can be efficiently managed by hormone replacement therapy in the human body comprise of menopause symptoms, osteoporosis, hypogonadism, gender dysphoria, endometriosis, and breast cancer.

Rising Prevalence of Hormonal Imbalance Disorders
Hormonal imbalance disorders can be referred to development of certain health conditions which are caused by abnormality in the production, regulation, and function of hormones in the human body. Some of the hormonal imbalance disorders which can affect both men and women includes polycystic ovary syndrome (PCOS), thyroid disorders, adrenal disorders, pituitary gland disorders, reproductive disorders, parathyroid disorders, and others. Major risk factors which can lead to development of hormonal imbalances in a person include genetic predisposition, age, lifestyle choices, medical conditions, and environmental changes.

Among various hormonal disorders, polycystic ovary syndrome (PCOS) is one of the most prevalent hormonal disorders affecting women of reproductive age. It is estimated that PCOS affects 5-10% of women of reproductive age worldwide. South Asia, Middle East, and North Africa are some of the regions which account for highest number of PCOS cases in recent years. According to the report published by BMC on Reproductive Biology and Endocrinology in 2021, it has been observed that India stood at highest position for around 22.7% PCOS cases being diagnosed in the country, followed by 20% cases in Philippines, 15.9% cases in Australia, 13.7% cases in United Kingdom, 12.2% cases in United States of America, and so on.

Hormone Replacement Therapy involves taking synthetic hormones to replace the hormones that are not being produced adequately by the body. In case of polycystic ovary syndrome (PCOS), hormone replacement therapy is used to regulate menstrual cycles, reduce hair growth, and remove acne. Another common hormonal disorders which are prevailing people of every age group and gender worldwide are thyroid disorders such as hypothyroidism and hyperthyroidism. According to World Health Organization (WHO), around 750 million people are suffering from some form of thyroid disorder in the world. The prevalence of thyroid disorders increases with age which account for around 20% women over 60 years of age having some form of thyroid dysfunction. In some regions, such as Southeast Asia, Africa, and South America around 50% of people are diagnosed with iodine deficiency every year which leads to the development of goiter (enlarged thyroid gland) and hypothyroidism. Moreover, effective results in management of various hormonal disorders after hormone replacement therapy are expected to register an impressive growth of global hormone replacement therapy market in the forecast period.


Download Free Sample Report

Growth in Geriatric Population

With increase in age, people tend to develop more symptoms of various hormonal imbalance disorders in their body. Some of the most common hormonal imbalances which affect people during their elder age include menopause, hypothyroidism, andropause, adrenal insufficiency, and diabetes. Among various hormonal disorders, menopause accounts for highest number of instances across various developing countries of the world. According to Menopause Foundation of Canada, by 2025, more than 1 billion women in the world will be experiencing menopause. Various kind of symptoms which are experienced by people during menopause comprise of hot flushes, vaginal dryness, night sweats, weight gain, and others. According to the report published by Forth with Life in 2019, it has been observed that around 73% of people suffer from hot flushes during menopause followed by 63% of people suffering from drowsiness, 47% people from low concentration, 43% people from memory troubles, and so on. Moreover, growth in worldwide geriatric population and rise in certain hormonal imbalances which are associated with people during their elder age are further expected to register a lucrative growth to global hormone replacement therapy market in the forecast period. According to the report published by Population Reference Bureau (PRB) based on countries with the oldest populations in the world, it has been concluded that Japan is the foremost country in the world accounting for around 28.2% of geriatric people out of total population, followed by Italy with 22.8% of geriatric population, Greece, and Portugal with 21.8 %, and Germany with 21.4% of geriatric people out of the total population.

Development of Healthcare Infrastructure
Improvement in medical facilities provided by various hospitals and medical centers around the world is one of the significant factors which is expected to propel the growth of global hormone replacement therapy market in the forecast period. Moreover, establishment of various healthcare associations around the world along with availability of skilled healthcare professionals are allowing more people to undergo hormone replacement therapy in their individual countries which is thereby driving the growth of the market.

Recent Developments

  • In June 2022, Halozyme Therapeutics, Inc. announced the commercial launch of TLANDO (testosterone undecanoate), an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
  • In February 2022, Pfizer Inc. and OPKO Health, Inc. announced that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA, a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.
  • In May 2021, Myovant Sciences GmbH announced that it received approval from the U.S. FDA for its hormone therapy Myfembree as a treatment for uterine fibroid bleeding. The drug launched by Myovant will give direct competition to AbbVie with an added dosing advantage.
  • In April 2021, TherapeuticsMD, Inc. and Theramex announced that they received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and Federal Agency of Medicines and Health Products (FAMPH) for the use of BIJUVE in U.K and under BIJUVA trade name in Belgium. The capsule will be used as a hormone replacement therapy.
  • Allergen Plc was procured by AbbVie in 2020. It is going to grow the portfolio to oncology, immunology, neuroscience, and so forth.
  • In December 2019, Pfizer, Inc. introduced a new drug known as Xtandi, which has received approval from U.S. FDA. This Xtandi is a combination of anti-hormone therapy and helps reduce cancer spreading. Pfizer completed the Weiss merger in December 2014, outpacing popular products such as Prempro and Premarin.

Market SegmentationGlobal hormone replacement therapy market is segmented based on product, route of administration, disease type, company, and region. In terms of product, the global hormone replacement therapy market is categorized into estrogen and progesterone replacement therapy, HGH replacement therapy, thyroid hormone replacement therapy, testosterone replacement therapy, and parathyroid hormone replacement. Based on, route of administration, the global hormone replacement therapy market is segmented into oral, parenteral, transdermal, and others. Based on disease type, the market is segmented into menopause, hypothyroidism, male hypogonadism, growth hormone deficiency, and hypoparathyroidism.

Market Players
Bayer AG, Pfizer Inc., Merck & Co., Inc., Viatris Inc., Novo Nordisk A/S, Eli Lilly and Company, F. Hoffmann-La Roche Ltd. (Genentech), Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.), ASCEND Therapeutics US, LLC. (Besins Healthcare), and AbbVie Inc.

Attribute

Details

Base Year

2022

Historic Data

2018 – 2021

Estimated Year

2023

Forecast Period

2024 – 2028

Quantitative Units

Revenue in USD Million, Volume in tons and CAGR for 2018-2022 and 2023-2028

Report coverage

Revenue forecast, Volume forecast, company share, competitive landscape, growth factors, and trends

Segments covered

Product

Route of Administration

Disease Type

Regional scope

North America; Asia Pacific; Europe; South America; Middle East & Africa

Country scope

United States; Canada; Mexico; China; India; Japan; Australia; South Korea; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; South Africa; UAE; Saudi Arabia;

Key companies profiled

Bayer AG, Pfizer Inc., Merck & Co., Inc., Viatris Inc., Novo Nordisk A/S, Eli Lilly and Company, F. Hoffmann-La Roche Ltd. (Genentech), Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.), ASCEND Therapeutics US, LLC. (Besins Healthcare), AbbVie Inc.

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Report Scope:
In this report, Global Hormone Replacement Therapy Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

·         Hormone Replacement Therapy Market, By Product:

o   Estrogen and Progesterone Replacement Therapy

o   HGH replacement therapy

o   Thyroid hormone replacement therapy

o   Testosterone Replacement Therapy

o   Parathyroid Hormone replacement

·         Hormone Replacement Therapy Market, By Route of Administration:

o   Oral

o   Parenteral

o   Transdermal

o   Others

·         Hormone Replacement Therapy Market, By Disease Type:

o   Menopause

o   Hypothyroidism

o   Male hypogonadism

o   Growth hormone deficiency

o   Hypoparathyroidism

·         Global Hormone Replacement Therapy Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Hormone Replacement Therapy Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Hormone Replacement Therapy Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Hormone Replacement Therapy Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value & Volume

5.2.  Market Share & Forecast

5.2.1.     By Product (Estrogen & Progesterone Replacement Therapy, HGH replacement therapy, Thyroid hormone replacement therapy, Testosterone Replacement Therapy, and Parathyroid Hormone replacement)

5.2.2.     By Route of Administration (Oral, Parenteral, Transdermal, and Others)

5.2.3.     By Disease Type (Menopause, Hypothyroidism, Male hypogonadism, Growth hormone deficiency, and Hypoparathyroidism)

5.2.4.     By Region

5.2.5.     By Company (2022)

5.3.  Product Market Map 

6.    North America Hormone Replacement Therapy Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value & Volume

6.2.  Market Share & Forecast

6.2.1.     By Product

6.2.2.     By Route of Administration

6.2.3.     By Disease Type

6.2.4.     By Country

6.3.  North America: Country Analysis

6.3.1.     United States Hormone Replacement Therapy Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value & Volume

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Product

6.3.1.2.2. By Route of Administration

6.3.1.2.3. By Disease Type

6.3.2.     Mexico Hormone Replacement Therapy Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value & Volume

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Product

6.3.2.2.2. By Route of Administration

6.3.2.2.3. By Disease Type

6.3.3.    Canada Hormone Replacement Therapy Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value & Volume

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Product

6.3.3.2.2. By Route of Administration

6.3.3.2.3. By Disease Type

7.    Europe Hormone Replacement Therapy Market Outlook

7.1.  Market Size & Forecast

7.1.1.     By Value & Volume

7.2.  Market Share & Forecast

7.2.1.     By Product

7.2.2.     By Route of Administration

7.2.3.     By Disease Type

7.2.4.     By Country

7.3   Europe: Country Analysis

7.3.1.    France Hormone Replacement Therapy Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value & Volume

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Product

7.3.1.2.2. By Route of Administration

7.3.1.2.3. By Disease Type

7.3.2.    Germany Hormone Replacement Therapy Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value & Volume

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Product

7.3.2.2.2. By Route of Administration

7.3.2.2.3. By Disease Type

7.3.3.    United Kingdom Hormone Replacement Therapy Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value & Volume

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Product

7.3.3.2.2. By Route of Administration

7.3.3.2.3. By Disease Type

7.3.4.    Italy Hormone Replacement Therapy Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value & Volume

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Product

7.3.4.2.2. By Route of Administration

7.3.4.2.3. By Disease Type

7.3.5.    Spain Hormone Replacement Therapy Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value & Volume

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Product

7.3.5.2.2. By Route of Administration

7.3.5.2.3. By Disease Type

8.    Asia-Pacific Hormone Replacement Therapy Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value & Volume

8.2.  Market Share & Forecast

8.2.1.     By Product

8.2.2.     By Route of Administration

8.2.3.     By Disease Type

8.2.4.     By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.     China Hormone Replacement Therapy Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value & Volume

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Product

8.3.1.2.2. By Route of Administration

8.3.1.2.3. By Disease Type

8.3.2.     India Hormone Replacement Therapy Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value & Volume

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Product

8.3.2.2.2. By Route of Administration

8.3.2.2.3. By Disease Type

8.3.3.     South Korea Hormone Replacement Therapy Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value & Volume

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Product

8.3.3.2.2. By Route of Administration

8.3.3.2.3. By Disease Type

8.3.4.     Japan Hormone Replacement Therapy Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value & Volume

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Product

8.3.4.2.2. By Route of Administration

8.3.4.2.3. By Disease Type

8.3.5.     Australia Hormone Replacement Therapy Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value & Volume

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Product

8.3.5.2.2. By Route of Administration

8.3.5.2.3. By Disease Type

9.    South America Hormone Replacement Therapy Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value & Volume

9.2.  Market Share & Forecast

9.2.1.     By Product

9.2.2.     By Route of Administration

9.2.3.     By Disease Type

9.2.4.     By Country

9.3.  South America: Country Analysis

9.3.1.     Brazil Hormone Replacement Therapy Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value & Volume

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Product

9.3.1.2.2. By Route of Administration

9.3.1.2.3. By Disease Type

9.3.2.     Argentina Hormone Replacement Therapy Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value & Volume

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Product

9.3.2.2.2. By Route of Administration

9.3.2.2.3. By Disease Type

9.3.3.     Colombia Hormone Replacement Therapy Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value & Volume

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Product

9.3.3.2.2. By Route of Administration

9.3.3.2.3. By Disease Type

10.  Middle East and Africa Hormone Replacement Therapy Market Outlook

10.1.  Market Size & Forecast

10.1.1.  By Value & Volume

10.2.              Market Share & Forecast

10.2.1.  By Product

10.2.2.  By Route of Administration

10.2.3.  By Disease Type

10.2.4.  By Country

10.3.              MEA: Country Analysis

10.3.1.  South Africa Hormone Replacement Therapy Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1.  By Value & Volume

10.3.1.2. Market Share & Forecast

10.3.1.2.1.  By Product

10.3.1.2.2.  By Route of Administration

10.3.1.2.3.  By Disease Type

10.3.2.  Saudi Arabia Hormone Replacement Therapy Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1.  By Value & Volume

10.3.2.2. Market Share & Forecast

10.3.2.2.1.  By Product

10.3.2.2.2.  By Route of Administration

10.3.2.2.3.  By Disease Type

10.3.3.  UAE Hormone Replacement Therapy Market Outlook

10.3.3.1.Market Size & Forecast

10.3.3.1.1.  By Value & Volume

10.3.3.2. Market Share & Forecast

10.3.3.2.1.  By Product

10.3.3.2.2.  By Route of Administration

10.3.3.2.3.  By Disease Type

11.  Market Dynamics

11.1.  Drivers

11.2.  Challenges

12.  Market Trends & Developments

13.  PESTLE Analysis

14.  Porter’s Five Forces Analysis

         14.1.  Competition in the Industry

14.2.  Potential of New Entrants

14.3.  Power of Suppliers

14.4.  Power of Customers

14.5.  Threat of Substitute Product

15.  Competitive Landscape 

15.1.    Business Overview

15.2.    Company Snapshot

15.3.    Products & Services

15.4.    Financials (In case of listed companies)

15.5.    Recent Developments

15.6.    SWOT Analysis

15.6.1.  Bayer AG

15.6.2.  Pfizer Inc.  

15.6.3.  Merck & Co., Inc.

15.6.4.  TherapeuticsMD, Inc.

15.6.5.  Novo Nordisk A/S

15.6.6.  AbbVie Inc.

15.6.7.  F. Hoffmann-La Roche Ltd. (Genentech)

15.6.8.  Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.)

15.6.9.  ASCEND Therapeutics US, LLC. (Besins Healthcare)

15.6.10.  Halozyme Therapeutics, Inc.

16.  Strategic Recommendations

17. About Us & Disclaimer

Figures and Tables

Frequently asked questions

Frequently asked questions

Growing prevalence of hormonal imbalance disorders across the world and development in worldwide healthcare infrastructure are driving the demand for the global hormone replacement therapy market.

Bayer AG, Pfizer Inc., Merck & Co., Inc., Viatris Inc., Novo Nordisk A/S, Eli Lilly and Company, F. Hoffmann-La Roche Ltd. (Genentech), Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.), ASCEND Therapeutics US, LLC. (Besins Healthcare), and AbbVie Inc. are some of the key players operating in the global hormone replacement therapy market.

Growth in worldwide geriatric population along with rise in prevalence of various hormonal disorders associated with people during their elder age are affecting the growth of the global hormone replacement therapy market in the forecast period. Specifically, women in elder age tend to face unpleasant condition such as hot flushes during menopause which convince the geriatric women to opt for hormone replacement therapy.

Based on product, estrogen and progesterone replacement therapy is dominating the market and is expected to maintain its dominance over the next five years due to increase in number of women reaching towards menopause.

Related Reports